Allena Pharma bereit für den Milliardenmarkt!
Seite 1 von 5 Neuester Beitrag: 04.07.22 18:31 | ||||
Eröffnet am: | 06.12.19 12:20 | von: moneywork4. | Anzahl Beiträge: | 111 |
Neuester Beitrag: | 04.07.22 18:31 | von: Nobsy11 | Leser gesamt: | 30.244 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | 4 | 5 5 > |
•Reloxaliase has a >80% probability of reaching commercial stage after reviewing the results of the URIROX-1 trial and the design of the URIROX-2 trial.
•Reloxaliase has a shot at $22 billion/year revenue opportunity just in the U.S. with a competitive advantage, yet the company's pipeline is being valued at just $45M.
•The stock is at a good Buy level after the recent pullback. Rating Buy, first price target=$4.50/share, time-frame=1-2 years.
https://seekingalpha.com/article/...maceuticals-rating-this-stock-buy
Latest News:
https://www.rttnews.com/3050506/...on-watch-alna-trims-workforce.aspx
Pipeline:
https://www.allenapharma.com/pipeline
Phase 3 Studie des Hauptkandidaten Reloxalase soll eingestellt werden
"Following a statistical analysis on unblinded data from the URIROX-2 Trial for reloxaliase in enteric hyperoxaluria, the management has decided to terminate the study. However, subject to negotiations with the contract research organization on payments, Allena (ALNA) says it plans to advance two mid-stage trials for ALLN-346 in the treatment of hyperuricemia.
“However, the company has limited financial resources, and there can be no assurance that these trials will be completed, or if completed, that they will be successful,” Allena
https://seekingalpha.com/news/...on-plans-to-end-trial-for-lead-asset
https://www.nasdaq.com/de/market-activity/stocks/alna/real-time
Es gibt auch ein Offering, aber was will man mit 2,8 Mio?
https://seekingalpha.com/news/...-pharmaceuticals-28m-direct-offering